Delivery Order SPE2DB20D3101-SPE2DB25FRRH2
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,406.80 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon DR 100s, with performance at the contractor's facility in Conshohocken, Pennsylvania. This is a firm fixed-price delivery order with an ultimate completion date of July 31, 2025, and represents a non-set-aside competitive award. The contract was issued on July 30, 2025, under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) vehicle...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules, valued at $36,394.49. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a non-competitive award under the company's existing contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of 36,000 units of Creon DR 100s capsules, valued at $6,150.38. This competitively awarded, firm fixed-price delivery order is set to be completed by July 30, 2025, and will be performed at the contractor's location in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical distributor supporting federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Creon DR 36,000 unit capsules in quantities of 100s, with a ceiling value of $12,946.57. This firm fixed-price delivery order, which is due for completion by July 29, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation, and performance...
- The Defense Logistics Agency awarded a delivery order valued at $3,088.91 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100 mg capsules. This non-competitive, firm fixed price delivery order was awarded on July 30, 2025, with an ultimate completion date of July 31, 2025. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. As a child contract under a larger vehicle, this delivery order represents a...
- The Defense Logistics Agency awarded a $2,376.88 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of 36,000 unit capsules of Creon 100s, a pancreatic enzyme replacement therapy. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,004.53 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100 capsules, with an ultimate completion date of July 30, 2025. This contract represents a firm fixed price delivery order with no set-aside designation, awarded competitively on July 29, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Creon DR is an enzyme replacement therapy used to treat...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Creon DR 36,000 Unit Capsule UU 100s, a pancreatic enzyme replacement medication. This non-competitive delivery order, valued at $3,116.73 with a firm fixed price structure, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The order is scheduled for completion by July 22, 2025, and will be fulfilled...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Creon DR 36,000 unit capsules (100 count bottles) valued at $4,260.68 under a firm fixed-price contract type. The contract was competitively awarded without set-aside designation and carries an ultimate completion date of July 25, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery order at its corporate office location...
- The Defense Logistics Agency awarded a $3,717.57 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules. The award, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location. This delivery order is issued under the company's existing Indefinite Delivery...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRRH2Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 24,000 units of Creon DR 100s capsules valued at $7,245.28. The contract utilizes firm fixed price pricing with no set-aside designation, indicating competitive award through open competition. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 30, 2025. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical federal medical procurement vendor, particularly for military and veteran healthcare systems. The company supplies a comprehensive range of pharmaceutical products and medical supplies through its extensive portfolio of DLA contracts, demonstrating capability to meet federal requirements for diverse therapeutic commodities. Creon DR, a pancreatic enzyme replacement therapy, supports the Defense Health Agency and other government healthcare systems' medical supply needs. The underlying IDC vehicle enables AmerisourceBergen to deliver pharmaceuticals, vaccines, and medical supplies globally to support military healthcare programs, with DLA planning to establish additional Pharmaceutical Prime Vendor Global Program Generation V contracts across multiple regions in the coming years.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 7/29/25 |